![Traws Pharma Inc](/common/images/company/N_TRAW.png)
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Nar... Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib's mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D). Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.19 | -26.0714285714 | 8.4 | 8.6099 | 6.21 | 42285 | 7.41084953 | CS |
4 | -0.58 | -8.54197349043 | 6.79 | 8.6099 | 5.44 | 55366 | 6.88845271 | CS |
12 | 1.66 | 36.4835164835 | 4.55 | 19.44 | 4.06 | 620589 | 11.92589547 | CS |
26 | -2.665 | -30.0281690141 | 8.875 | 19.44 | 4.06 | 303666 | 11.47470399 | CS |
52 | -18.54 | -74.9090909091 | 24.75 | 24.75 | 4.06 | 219050 | 12.13275108 | CS |
156 | -18.54 | -74.9090909091 | 24.75 | 24.75 | 4.06 | 219050 | 12.13275108 | CS |
260 | -18.54 | -74.9090909091 | 24.75 | 24.75 | 4.06 | 219050 | 12.13275108 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales